Trachoma

• Published in: Nature reviews. Disease primers Vol. 8; no. 1; p. 32
• Main Authors: Solomon, Anthony W., Burton, Matthew J., Gower, Emily W., Harding-Esch, Emma M., Oldenburg, Catherine E., Taylor, Hugh R., Traoré, Lamine
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 26.05.2022; Nature Publishing Group
• Subjects: 692/699/255/1318; 692/699/3161; 692/699/3161/3166; 692/699/3161/3178; Blindness - etiology; Cancer Research; Child; Chlamydia; Chlamydia trachomatis; Epidemiology; Gonorrhea - complications; Humans; Infections; Internal Medicine; Medical Microbiology; Medicine; Medicine & Public Health; Primer; Public health; Quality of Life Research; Trachoma - complications; Trachoma - epidemiology; Trachoma - prevention & control; Trichiasis - complications; Trichiasis - etiology
• ISSN: 2056-676X; 2056-676X
• DOI: 10.1038/s41572-022-00359-5

Trachoma is a neglected tropical disease caused by infection with conjunctival strains of Chlamydia trachomatis. It can result in blindness. Pathophysiologically, trachoma is a disease complex composed of two linked chronic processes: a recurrent, generally subclinical infectious–inflammatory disease that mostly affects children, and a non-communicable, cicatricial and, owing to trichiasis, eventually blinding disease that supervenes in some individuals later in life. At least 150 infection episodes over an individual’s lifetime are needed to precipitate trichiasis; thus, opportunity exists for a just global health system to intervene to prevent trachomatous blindness. Trachoma is found at highest prevalence in the poorest communities of low-income countries, particularly in sub-Saharan Africa; in June 2021, 1.8 million people worldwide were going blind from the disease. Blindness attributable to trachoma can appear in communities many years after conjunctival C. trachomatis transmission has waned or ceased; therefore, the two linked disease processes require distinct clinical and public health responses. Surgery is offered to individuals with trichiasis and antibiotic mass drug administration and interventions to stimulate facial cleanliness and environmental improvement are designed to reduce infection prevalence and transmission. Together, these interventions comprise the SAFE strategy, which is achieving considerable success. Although much work remains, a continuing public health problem from trachoma in the year 2030 will be difficult for the world to excuse. Trachoma, caused by infection with conjunctival strains of Chlamydia trachomatis , is the most common infectious cause of blindness. This Primer summarizes the epidemiology, pathophysiology and diagnosis of trachoma as well as its management, disease control and elimination, and key areas for future research.